通过天眼查大数据分析，浙江我武生物科技股份有限公司共对外投资了6家企业，参与招投标项目337 次，知识产权方面有商标信息38条，专利信息20条，此外企业还拥有行政许可63个。 来源：金融界 资金流向方面，今日主力资金净流出5820.70万元，占比成交额13.26%。其中，超大单净流出2538.91万 元、占成交额5.78%，大单净流出3281.78万元、占成交额7.48%，中单净流出流出993.77万元、占成交 额2.26%，小单净流入6814.46万元、占成交额15.52%。 我武生物最新一期业绩显示，截至2025一季报，公司营业总收入2.28亿元、同比增长5.65%，归属净利 润7434.21万元，同比减少3.71%，扣非净利润7361.84万元，同比增长1.48%，流动比率19.060、速动比 率18.379、资产负债率5.42%。 天眼查商业履历信息显示，浙江我武生物科技股份有限公司，成立于2002年，位于湖州市，是一家以从 事医药制造业为主的企业。企业注册资本52358.4万人民币，实缴资本52358.4万人民币。公司法定代表 人为胡赓熙。 金融界消息 截至2025年7月30日收盘，我武生物（300 ...

Group 1 - The core viewpoint of the news is that Shandong Lukang Pharmaceutical Co., Ltd. has shown a mixed financial performance in the latest quarter, with a decline in total revenue but an increase in net profit [1] - As of July 30, 2025, the company's stock price closed at 10.59 yuan, down 1.3%, with a turnover rate of 7.03% and a trading volume of 631,900 hands, amounting to 672 million yuan [1] - The company's latest quarterly report indicates total operating revenue of 1.674 billion yuan, a year-on-year decrease of 6.95%, while net profit attributable to shareholders reached 78.5976 million yuan, a year-on-year increase of 16.77% [1] Group 2 - The company has a current ratio of 1.279, a quick ratio of 0.862, and a debt-to-asset ratio of 54.65% [1] - Shandong Lukang Pharmaceutical has made investments in 17 enterprises and participated in 5,000 bidding projects, showcasing its active engagement in the market [2] - The company holds 187 trademark registrations and 240 patents, along with 313 administrative licenses, indicating a strong intellectual property portfolio [2]

金融界消息 截至2025年7月30日收盘，圣湘生物（688289）报收于22.26元，下跌1.81%，换手率 1.63%，成交量9.42万手，成交金额2.11亿元。 资金流向方面，今日主力资金净流出4389.43万元，占比成交额20.82%。其中，超大单净流出2758.48万 元、占成交额13.08%，大单净流出1630.95万元、占成交额7.73%，中单净流出流入1222.60万元、占成 交额5.8%，小单净流入3166.82万元、占成交额15.02%。 天眼查商业履历信息显示，圣湘生物科技股份有限公司，成立于2008年，位于长沙市，是一家以从事医 药制造业为主的企业。企业注册资本57938.8006万人民币，实缴资本12648.8642万人民币。公司法定代 表人为戴立忠。 通过天眼查大数据分析，圣湘生物科技股份有限公司共对外投资了27家企业，参与招投标项目1046次， 知识产权方面有商标信息387条，专利信息467条，此外企业还拥有行政许可311个。 来源：金融界 圣湘生物最新一期业绩显示，截至2025一季报，公司营业总收入4.75亿元、同比增长21.62%，归属净利 润9173.55万元，同比增长13. ...

Group 1 - The company announced that its controlling shareholder, Ningbo Yinyi Holdings Co., Ltd., is planning a share transfer that may lead to a change in the controlling shareholder and actual controller [2] - The company's stock was suspended from trading starting July 31, with an expected suspension period of no more than two trading days [2] - On July 30, the company's stock price hit the daily limit, closing at 8.02 yuan per share, with a market capitalization exceeding 2.9 billion yuan [2] Group 2 - In 2024, the company achieved operating revenue of 212 million yuan, a year-on-year increase of 12.81%, and a net profit of 79.25 million yuan, compared to a net loss of 11.56 million yuan in 2023 [2] - The strong performance was attributed to robust growth in the pharmaceutical intermediates business and steady improvement in the urea business, although challenges remain in cost control and market expansion [2] - For 2025, the company plans to expand its existing product supply chain, enhance management efficiency, increase R&D investment, and support the strategic transformation of its main business, Nansong Pharmaceutical [3] Group 3 - In Q1 2025, the company reported operating revenue of 40.83 million yuan, a year-on-year decline of 34.05%, and a net profit of 1.36 million yuan, compared to a net loss of 116,000 yuan in the same period last year [3] - The company aims to overcome challenges such as significant fluctuations in the urea market and the diminishing brand effect of its urea products [3]

资金流向方面，今日主力资金净流出3686.75万元，占比成交额4.99%。其中，超大单净流出4517.51万 元、占成交额6.11%，大单净流入830.77万元、占成交额1.12%，中单净流出流入2257.57万元、占成交 额3.05%，小单净流入1429.18万元、占成交额1.93%。 通过天眼查大数据分析，江苏诺泰澳赛诺生物制药股份有限公司共对外投资了13家企业，参与招投标项 目192次，知识产权方面有商标信息13条，专利信息123条，此外企业还拥有行政许可397个。 来源：金融界 ST诺泰最新一期业绩显示，截至2025一季报，公司营业总收入5.66亿元、同比增长58.96%，归属净利润 1.53亿元，同比增长130.10%，扣非净利润1.52亿元，同比增长131.79%，流动比率1.062、速动比率 0.732、资产负债率47.86%。 天眼查商业履历信息显示，江苏诺泰澳赛诺生物制药股份有限公司，成立于2009年，位于连云港市，是 一家以从事医药制造业为主的企业。企业注册资本21318.38万人民币，实缴资本15690.785万人民币。公 司法定代表人为童梓权。 金融界消息 截至2025年7月30日收盘 ...

资金流向方面，今日主力资金净流出2544.07万元，占比成交额6.18%。其中，超大单净流出265.02万 元、占成交额0.64%，大单净流出2279.05万元、占成交额5.54%，中单净流出流入551.82万元、占成交 额1.34%，小单净流入1992.25万元、占成交额4.84%。 来源：金融界 普洛药业最新一期业绩显示，截至2025一季报，公司营业总收入27.30亿元、同比减少14.63%，归属净 利润2.49亿元，同比增长1.98%，扣非净利润2.06亿元，同比减少14.05%，流动比率1.505、速动比率 1.203、资产负债率44.93%。 金融界消息 截至2025年7月30日收盘，普洛药业（000739）报收于16.44元，下跌1.67%，换手率 2.15%，成交量24.94万手，成交金额4.11亿元。 通过天眼查大数据分析，普洛药业股份有限公司共对外投资了19家企业，参与招投标项目24次，知识产 权方面有商标信息125条，专利信息173条，此外企业还拥有行政许可7个。 天眼查商业履历信息显示，普洛药业股份有限公司，成立于1997年，位于金华市，是一家以从事医药制 造业为主的企业。企业注册资本1 ...

Group 1 - The core viewpoint of the news indicates that ST Unimed (002581) has experienced a decline in stock price and significant net outflow of funds, reflecting investor sentiment and market activity [1][3] - As of July 30, 2025, ST Unimed's stock closed at 7.21 yuan, down 2.44%, with a turnover rate of 3.19% and a trading volume of 128,000 hands, amounting to a transaction value of approximately 93.30 million yuan [1] - The latest financial performance report for ST Unimed shows total operating revenue of 35.33 million yuan, a year-on-year decrease of 57.84%, and a net profit attributable to shareholders of 36.85 million yuan, down 33.01% year-on-year [1] Group 2 - The company has made significant investments, with a total of 11 external investments and participation in 7 bidding projects, indicating active engagement in business expansion [2] - ST Unimed holds 4 administrative licenses, which may enhance its operational capabilities and regulatory compliance [2] - The company, established in 2000 and located in Zibo City, primarily operates in the pharmaceutical manufacturing industry, with a registered capital of approximately 6.60 billion yuan [1][2]

Group 1 - Guizhou Sanli (SH 603439) announced a board meeting on July 30, 2025, to discuss the proposal for repurchasing and canceling part of the restricted stock [1] - For the year 2024, Guizhou Sanli's revenue composition is 99.97% from the pharmaceutical manufacturing industry and 0.03% from other businesses [1] - As of the report date, Guizhou Sanli has a market capitalization of 5.4 billion yuan [1]

通过天眼查大数据分析，奥精医疗科技股份有限公司共对外投资了8家企业，参与招投标项目130次，知 识产权方面有商标信息48条，专利信息134条，此外企业还拥有行政许可21个。 来源：金融界 资金流向方面，今日主力资金净流出1472.89万元，占比成交额18.82%。其中，超大单净流出321.15万 元、占成交额4.1%，大单净流出1151.74万元、占成交额14.72%，中单净流出流入968.61万元、占成交 额12.38%，小单净流入504.27万元、占成交额6.44%。 奥精医疗最新一期业绩显示，截至2025一季报，公司营业总收入4245.97万元、同比减少10.35%，归属 净利润104.15万元，同比减少84.99%，扣非净利润234.15万元，同比减少168.21%，流动比率18.403、速 动比率16.987、资产负债率8.65%。 天眼查商业履历信息显示，奥精医疗科技股份有限公司，成立于2004年，位于北京市，是一家以从事医 药制造业为主的企业。企业注册资本13555.1584万人民币，实缴资本13555.1584万人民币。公司法定代 表人为胡刚。 金融界消息 截至2025年7月30日收盘，奥精医 ...

资金流向方面，今日主力资金净流出1341.37万元，占比成交额1.74%。其中，超大单净流出3038.77万 元、占成交额3.95%，大单净流入1697.40万元、占成交额2.21%，中单净流出流出1314.66万元、占成交 额1.71%，小单净流入2656.03万元、占成交额3.45%。 美诺华最新一期业绩显示，截至2025一季报，公司营业总收入2.76亿元、同比增长5.22%，归属净利润 2122.17万元，同比增长51.12%，扣非净利润1662.24万元，同比减少19.02%，流动比率1.206、速动比率 0.651、资产负债率50.05%。 天眼查商业履历信息显示，宁波美诺华药业股份有限公司，成立于2004年，位于宁波市，是一家以从事 医药制造业为主的企业。企业注册资本21982.2861万人民币，实缴资本9000万人民币。公司法定代表人 为姚成志。 通过天眼查大数据分析，宁波美诺华药业股份有限公司共对外投资了16家企业，参与招投标项目6次， 知识产权方面有商标信息1条，专利信息27条，此外企业还拥有行政许可9个。 来源：金融界 金融界消息 截至2025年7月30日收盘，美诺华（603538）报收于 ...